Multiple Myeloma Market

The multiple myeloma market size is projected to reach $53,521.76 million by 2031, registering a CAGR of 10.5% from 2022 to 2031.

PORTLAND, OREGON, UNITED STATES, February 21, 2024 /EINPresswire.com/ -- According to the report published by Allied Market Research, the global multiple myeloma market garnered $19.66 billion in 2021 and is estimated to generate $53.52 billion by 2031, manifesting a CAGR of 10.5% from 2022 to 2031. The report provides an extensive analysis of changing market dynamics, major segments, value chains, competitive scenarios, and regional landscapes. This research offers valuable guidance to leading players, investors, shareholders, and startups in devising strategies for sustainable growth and gaining a competitive edge in the market.

Market Size By 2031 USD 53.5 billion
Growth Rate CAGR of 10.5%
Forecast period 2021 – 2031
Report Pages 411

𝑹𝒆𝒒𝒖𝒆𝒔𝒕 𝑺𝒂𝒎𝒑𝒍𝒆 𝑪𝒐𝒑𝒚 𝒐𝒇 𝒕𝒉𝒆 𝑹𝒆𝒑𝒐𝒓𝒕 𝑯𝒆𝒓𝒆-
https://www.alliedmarketresearch.com/request-sample/3725

The protease inhibitors segment is anticipated to lead the global multiple myeloma market by 2031, contributing over one-third of the revenue and demonstrating the fastest compound annual growth rate (CAGR) of 11.1% throughout the forecast period. Other segments such as chemotherapy, monoclonal antibody, and others are also analyzed in the report.

In terms of end users, hospitals held the highest share of the market revenue in 2021, comprising nearly two-thirds of the total, and are expected to maintain this lead with the fastest CAGR of 10.7% during the forecast period. Clinics and other segments were also evaluated in the study.

Regarding disease type, active multiple myeloma accounted for the largest share in 2021, representing more than four-fifths of the global market revenue and is projected to continue dominating with the fastest CAGR of 10.6% throughout the forecast period. The report also discusses the smoldering multiple myeloma segment.

Regionally, North America dominated the market in 2021, capturing over one-third of the revenue and is forecasted to maintain its dominance by 2031. Conversely, the Asia-Pacific region is expected to exhibit the fastest CAGR of 11.2% throughout the forecast period. The report also covers Europe and LAMEA regions.

𝑭𝒐𝒓 𝑷𝒖𝒓𝒄𝒉𝒂𝒔𝒆 𝑰𝒏𝒒𝒖𝒊𝒓𝒚- https://www.alliedmarketresearch.com/purchase-enquiry/3725

𝐓𝒐𝒑 𝑴𝒖𝒍𝒕𝒊𝒑𝒍𝒆 𝑴𝒚𝒆𝒍𝒐𝒎𝒂 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬
Sanofi
Takeda Pharmaceutical Company Ltd
AbbVie Inc
Pfizer Inc.
Novartis AG
Baxter International Inc.
Bristol-Myers Squibb Company
Teva Pharmaceutical Industries
Johnson & Johnson
Amgen Inc.

𝑻𝒓𝒆𝒏𝒅𝒊𝒏𝒈 𝑹𝒆𝒑𝒐𝒓𝒕𝒔 𝒊𝒏 𝑯𝒆𝒂𝒍𝒕𝒉𝒄𝒂𝒓𝒆 𝑰𝒏𝒅𝒖𝒔𝒕𝒓𝒚-
𝑷𝒉𝒂𝒓𝒎𝒂𝒄𝒆𝒖𝒕𝒊𝒄𝒂𝒍 𝑭𝒊𝒍𝒕𝒓𝒂𝒕𝒊𝒐𝒏 𝑴𝒂𝒓𝒌𝒆𝒕 https://www.alliedmarketresearch.com/pharmaceutical-filtration-market-A06060
𝑺𝒕𝒆𝒓𝒊𝒍𝒊𝒛𝒂𝒕𝒊𝒐𝒏 𝑺𝒆𝒓𝒗𝒊𝒄𝒆𝒔 𝑴𝒂𝒓𝒌𝒆𝒕 https://www.alliedmarketresearch.com/sterilization-services-market-A07513

David Correa
Allied Market Research
+ +1 5038946022
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.